Osteoporosis and Bisphosphonate-Related Osteonecrosis of the Jaw Bone

Table 1

Patients’ characteristics, osteonecrosis of the jaw and dental treatments.

	Total (𝑁=76)
	𝑛 (%)
Age category
50–60	14 (18.4)
61–70	27 (35.5)
71–79	28 (36.9)
80+	7 (9.2)
Median (IQR)	69 (62–74)
Smoking status
Never	56 (73.7)
Current	9 (11.8)
Former	11 (14.5)
Medical history
Hypertension
No	50 (65.8)
Yes	26 (34.2)
Cardiovascular disease
No	60 (78.9)
Yes	16 (21.1)
Immunosuppressant
No	72 (94.7)
Yes	4 (5.3)
Previous radio/chemotherapy
No	73 (96.1)
Yes	3 (3.9)
BPs and BRONJ
BPs treatment
Alendronate	47 (61.8)
Clodronate	16 (21.1)
Ibandronate	3 (3.9)
Risedronate	10 (13.2)
ONJ at first visit
No	69 (90.8)
Yes	7 (9.2)
ONJ Stage
0	57 (89.1)
I	3 (4.7)
II	4 (6.3)
ONJ Site
Maxilla	1 (14.3)
Jaw Bone	6 (85.7)
Oral care
Minor ONJ surgery
No	72 (94.7)
Yes	4 (5.3)
Dental treatment
No	31 (40.8)
Yes	45 (59.2)

ONJ: Osteonecrosis of the jaw; BPs: Bisphosphonates.